ZYDUSLIFE Zydus Lifesciences Ltd Product Launches Announcement 2025 - USFDA Approval Zydus Lifesciences Ltd received tentative approval from the USFDA on June 2, 2025, for its Rifaximin Tablets (550 mg), which treat irritable bowel syndrome. The US sales for Rifaximin tablets were USD 2,672.9 million as of March 2025..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd